A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer
Zhi Yang, Wei-Da Fu, Hua-Yan Gu, Jia-Ling Ding, Gui-Long Guo Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of ChinaCorrespondence: Gui-Long Guo, Email guoguilong@sina.comPurpose: To explore the efficacy a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-retrospective-real-world-study-of-pyrotinib-in-her-2-positive-advanc-peer-reviewed-fulltext-article-CMAR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232782576418816 |
|---|---|
| author | Yang Z Fu WD Gu HY Ding JL Guo GL |
| author_facet | Yang Z Fu WD Gu HY Ding JL Guo GL |
| author_sort | Yang Z |
| collection | DOAJ |
| description | Zhi Yang, Wei-Da Fu, Hua-Yan Gu, Jia-Ling Ding, Gui-Long Guo Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of ChinaCorrespondence: Gui-Long Guo, Email guoguilong@sina.comPurpose: To explore the efficacy and safety of pyrotinib in a real-world setting in a population with HER2-positive advanced breast cancer, subgroup analysis was conducted based on different clinicopathological features to further explore the general characteristics of patients, tumor nature, and the effect of various lines of treatment before patients started pyrotinib on the efficacy of pyrotinib in the real-world study.Methods: The clinical pathological characteristics, drug efficacy and related adverse reactions of HER2-positive MBC patients treated with pyrotinib in six hospitals in Southeast Zhejiang Province from February 2018 to December 2023 were collected and analyzed retrospectively.Results: A total of 342 patients with HER2-positive MBC were enrolled. The median follow-up time of 42.0 months. The median age of the overall population was 52 years (range from 25– 90 year old). Median progression-free survival in the total population was 10.0 months, the median overall survival was 29.0 months. The (objective response rate, ORR) was 40.35% and the (disease control rate, DCR) was 83.92%. The median progression-free survival (PFS) in the total population was 10.0 months, the median overall survival was 29.0 months. And pyrotinib had better mPFS for advanced first-line treatment than for second-third-line and beyond(14.0 months vs.10.0 months vs.6.0 months, P< 0.001). Multivariate Cox regression analysis showed that ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS. Diarrhea was the most common adverse reaction (ADR) in 205 patients (59.94%), which could be controlled by antidiarrheal drugs.Conclusion: This multicenter study suggested that the use of pyrotinib for HER2 positive MBC had a relatively good efficacy, especially for those who received first-line pyrotinib treatment and those who were sensitive to previous trastuzumab treatment. Patients with brain metastasis and liver metastases also benefit from pyrotinib treatment, especially for patients treated with brain radiotherapy and/or surgery. ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS in HER2 Positive MBC patients treated with pyrotinib. The most common adverse reaction associated with pyrotinib is diarrhea, which can be well controlled through antidiarrheal treatment. Pyrotinib combined with vinorelbine has similar efficacy to pyrotinib combined with capecitabine and has fewer side effects, and can be used as an alternative to capecitabine.Keywords: pyrotinib, HER2 positive metastatic breast cancer, real-world study, efficacy, safety |
| format | Article |
| id | doaj-art-60a4ea949a8a4b9dbb4dc85188904fe1 |
| institution | OA Journals |
| issn | 1179-1322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj-art-60a4ea949a8a4b9dbb4dc85188904fe12025-08-20T02:03:05ZengDove Medical PressCancer Management and Research1179-13222025-03-01Volume 17441460100764A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast CancerYang ZFu WDGu HYDing JLGuo GLZhi Yang, Wei-Da Fu, Hua-Yan Gu, Jia-Ling Ding, Gui-Long Guo Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of ChinaCorrespondence: Gui-Long Guo, Email guoguilong@sina.comPurpose: To explore the efficacy and safety of pyrotinib in a real-world setting in a population with HER2-positive advanced breast cancer, subgroup analysis was conducted based on different clinicopathological features to further explore the general characteristics of patients, tumor nature, and the effect of various lines of treatment before patients started pyrotinib on the efficacy of pyrotinib in the real-world study.Methods: The clinical pathological characteristics, drug efficacy and related adverse reactions of HER2-positive MBC patients treated with pyrotinib in six hospitals in Southeast Zhejiang Province from February 2018 to December 2023 were collected and analyzed retrospectively.Results: A total of 342 patients with HER2-positive MBC were enrolled. The median follow-up time of 42.0 months. The median age of the overall population was 52 years (range from 25– 90 year old). Median progression-free survival in the total population was 10.0 months, the median overall survival was 29.0 months. The (objective response rate, ORR) was 40.35% and the (disease control rate, DCR) was 83.92%. The median progression-free survival (PFS) in the total population was 10.0 months, the median overall survival was 29.0 months. And pyrotinib had better mPFS for advanced first-line treatment than for second-third-line and beyond(14.0 months vs.10.0 months vs.6.0 months, P< 0.001). Multivariate Cox regression analysis showed that ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS. Diarrhea was the most common adverse reaction (ADR) in 205 patients (59.94%), which could be controlled by antidiarrheal drugs.Conclusion: This multicenter study suggested that the use of pyrotinib for HER2 positive MBC had a relatively good efficacy, especially for those who received first-line pyrotinib treatment and those who were sensitive to previous trastuzumab treatment. Patients with brain metastasis and liver metastases also benefit from pyrotinib treatment, especially for patients treated with brain radiotherapy and/or surgery. ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS in HER2 Positive MBC patients treated with pyrotinib. The most common adverse reaction associated with pyrotinib is diarrhea, which can be well controlled through antidiarrheal treatment. Pyrotinib combined with vinorelbine has similar efficacy to pyrotinib combined with capecitabine and has fewer side effects, and can be used as an alternative to capecitabine.Keywords: pyrotinib, HER2 positive metastatic breast cancer, real-world study, efficacy, safetyhttps://www.dovepress.com/a-retrospective-real-world-study-of-pyrotinib-in-her-2-positive-advanc-peer-reviewed-fulltext-article-CMARpyrotinibher2 positive metastatic breast cancerreal-world study;efficacy;safety |
| spellingShingle | Yang Z Fu WD Gu HY Ding JL Guo GL A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer Cancer Management and Research pyrotinib her2 positive metastatic breast cancer real-world study;efficacy;safety |
| title | A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer |
| title_full | A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer |
| title_fullStr | A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer |
| title_full_unstemmed | A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer |
| title_short | A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer |
| title_sort | retrospective real world study of pyrotinib in her 2 positive advanced breast cancer |
| topic | pyrotinib her2 positive metastatic breast cancer real-world study;efficacy;safety |
| url | https://www.dovepress.com/a-retrospective-real-world-study-of-pyrotinib-in-her-2-positive-advanc-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT yangz aretrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT fuwd aretrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT guhy aretrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT dingjl aretrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT guogl aretrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT yangz retrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT fuwd retrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT guhy retrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT dingjl retrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer AT guogl retrospectiverealworldstudyofpyrotinibinher2positiveadvancedbreastcancer |